

PlexPCR[®] Flu/RSV/SARS-CoV-2

Upfront Diagnosis


IVDR
Certified

Prompt identification of clinically relevant seasonal respiratory viruses

- ▶ Stay ahead of seasonal influenza that results in substantial worldwide disease burden¹
- ▶ RSV is a common cause of respiratory infections and the main cause of severe cases of bronchiolitis and pneumonia in infants and young children^{2,3}
- ▶ Confidently detect SARS-CoV-2, including current known circulating variants⁴

Triage and diagnose important respiratory viruses upfront

- ▶ Influenza A
- ▶ Influenza B
- ▶ Respiratory Syncytial Virus (A and B)
- ▶ SARS-CoV-2



Improve laboratory productivity during seasonal testing surges

- ▶ Maximise your output with this single-well multiplex test.
- ▶ Conveniently utilise your existing QuantStudio™ 5 instruments.
- ▶ Enjoy scalable throughput. Our flexible workflow easily adapts to fluctuating test demand.
- ▶ Our smart technology utilises cost-effective components, allowing us to produce affordable assays for you.

PlexPCR® Flu/RSV/SARS-CoV-2 is a Class B IVDR certified, single-well multiplex qPCR test detecting clinically relevant seasonal respiratory viruses Influenza A, Influenza B, Respiratory Syncytial Virus (A & B) and SARS-CoV-2 virus, plus an endogenous control⁵.

Powered by proprietary **PlexPCR®** technology demonstrating improved multiplex performance compared with other probe-based tests.⁶

Well	Channel	Target	Clinical evaluation of PlexPCR® Flu/RSV/SARS-CoV-2 ⁵				
1	1	Flu A		Flu A	Flu B	RSV	SARS-CoV-2
	2	Flu B					
	3	RSV A and RSV B	Sensitivity	100.00%	94.60%	97.20%	99.00%
	4	SARS-CoV-2 (ORF1ab and RdRp)	Specificity	99.00%	99.30%	98.90%	95.80%
	5	Endogenous Control					

Validated with nasopharyngeal swabs.⁵

Adopt **PlexPCR®** Flu/RSV/SARS-CoV-2 today!

Product	Compatible	Size	Cat#
PlexPCR® Flu/RSV/SARS-CoV-2	QuantStudio 5	192 reactions†	1703192
Recommended Positive Control	Compatible	Size	Cat#
Positive Control Flu/RSV/SARS	QuantStudio 5	2 x swabs	95006

References: 1. Timothy M Uyeki, David S Hui, Maria Zambon, David E Wentworth, Arnold S Monto (August 2022) Influenza, The Lancet, Seminar Volume 400, Issue 10353, P693-706, August 27, 2022 [https://doi.org/10.1016/S0140-6736\(22\)00982-5](https://doi.org/10.1016/S0140-6736(22)00982-5) 2. Borchers AT, Chang C, Gershwin ME, Gershwin LJ (2013) Respiratory syncytial virus—a comprehensive review. Clin Rev Allergy Immunol 45: 331–379. 10.1007/s12016-013-8368-9 3. Jain H, Schweitzer JW, Justice NA. Respiratory Syncytial Virus Infection. [Updated 2023 Jun 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan <https://www.ncbi.nlm.nih.gov/books/NBK459215/> 4. <https://www.who.int/activities/tracking-SARS-CoV-2-variants> 5. **PlexPCR®** Flu/RSV/SARS-CoV-2 Instructions for use 6. Mokany E., Tan Y.L., Bone S.M., Fuery C., Todd A.V., 2013. MNazyme qPCR with superior multiplexing capacity. Clin. Chem. 59(2): 419-426

PlexPCR® Flu/RSV/SARS-CoV-2 and RespiVirus kits are developed and manufactured by **SpeedDx** Pty Ltd, Sydney. **PlexPCR®** & **SpeedDx®** are registered trademarks of **SpeedDx** Pty Ltd. Other copyright and trademarks are the property of the respective owners. **SpeedDx** Pty. Ltd. products may be covered by one or more local or foreign patents. Visit www.plexpcr.com/patents for comprehensive patent information.

†Additional volumes provided for use with liquid handling systems **PlexPCR®** Flu/RSV/SARS-CoV-2 is only available for sale in the E.U.

Australia - SpeedDx Pty. Ltd.

+61 (0)2 9209 4170

sales@speedx.com.au

Europe - SpeedDx Ltd.

+44 (0)330 445 0036

sales.uk@speedx.com.au

Find out more **speedxpcr.com**

